Ali Ghaleiha

Ali Ghaleiha


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
AGAli Ghaleiha
Ali Ghaleiha
NENeda Entezari
Neda Entezari
AMAmirhossein Modabbernia
Amirhossein Modabbernia
BNBabak Najand
Babak Najand
NANeda Askari
Neda Askari
SAShahin Akhondzadeh
Shahin Akhondzadeh

1 May 2013 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
AGAli Ghaleiha
Ali Ghaleiha
MAMahtab Asadabadi
Mahtab Asadabadi
MMMohammad-Reza Mohammadi
Mohammad-Reza Mohammadi
MSMaryam Shahei
Maryam Shahei
MTMina Tabrizi
Mina Tabrizi
SAShahin Akhondzadeh
Shahin Akhondzadeh
Autism is a neurodevelopmental disorder that causes significant impairment in socialization and communication. It is also associated with ritualistic and stereotypical behaviour. Recent studies propose both hyper-and hypoglutamatergic ideologies for autism. The objective of this study was to assess the effects of memantine plus risperidone in the treatment of children with autism. Children with autism were randomly allocated to risperidone plus memantine or placebo plus risperidone for a 10-wk, double-blind, placebo-controlled study. The dose of risperidone was titrated up to 3 mg/d and memantine was titrated to 20 mg/d. Children were assessed at baseline and after 2, 4, 6, 8 and 10 wk of starting medication protocol. The primary outcome measure was the irritability subscale of Aberrant Behavior Checklist–Community (ABC-C). Difference between the two treatment arms was significant as the group that received memantine had greater reduction in ABC-C subscale scores for irritability, stereotypic behaviour and hyperactivity. Eight side-effects were observed over the trial, out of the 25 side-effects that the checklist included. The difference between the two groups in the frequency of side-effects was not significant. The present study suggests that memantine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated. This trial is registered with the Iranian Clinical Trials Registry (IRCT1138901151556N10; www.irct.ir)

23 January 2015 in Depression and Anxiety
Verified
Journal Article
Closed access
PDF file
AZAtefeh Zeinoddini
Atefeh Zeinoddini
MSMaryam Sorayani
Maryam Sorayani
EHElmira Hassanzadeh
Elmira Hassanzadeh
MAMohammad Arbabi
Mohammad Arbabi
MFMehdi Farokhnia
Mehdi Farokhnia
SAShahin Akhondzadeh
Shahin Akhondzadeh
Background The antidepressive effect of pioglitazone has been noted in patients with major depressive disorder in absence of metabolic syndrome. This study was conducted to evaluate the safety and efficacy of pioglitazone in patients with bipolar depression without concomitant metabolic syndrome or diabetes. Method Forty‐eight outpatients with the diagnosis of bipolar I disorder and a major depressive episode participated in a parallel, randomized, double‐blind, placebo‐controlled trial, and 44 patients underwent 6‐week treatment with either pioglitazone (30 mg/day) or placebo as an adjunctive treatment to lithium. Therapeutic serum lithium levels of 0.6–0.8 mEq/L were required for two or more consecutive weeks immediately before starting pioglitazone and during the 6‐week study. Patients were evaluated using Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) at baseline and weeks 1, 2, 4, and 6. The primary outcome was to evaluate the efficacy of pioglitazone in improving the depressive symptoms. Result General linear model repeated measures showed significant effect for time × treatment interaction on the HDRS scores [F(2.78, 116.65) = 4.77, P = .005]. Significantly greater reduction was observed in HDRS scores in the pioglitazone group than the placebo group from baseline HDRS score at weeks 2, 4, and 6, P = .003, .006, and .006, respectively. No serious adverse event was observed. Conclusion This study showed that pioglitazone could be a tolerable and effective adjunctive therapy for improving depressive symptoms in bipolar disorder without type 2 diabetes or metabolic syndrome.

12 December 2012 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
AMAmirhossein Modabbernia
Amirhossein Modabbernia
FRFarzin Rezaei
Farzin Rezaei
BSBahman Salehi
Bahman Salehi
MJMorteza Jafarinia
Morteza Jafarinia
MAMandana Ashrafi
Mandana Ashrafi
SAShahin Akhondzadeh
Shahin Akhondzadeh

20 August 2015 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
SASomayeh Arabzadeh
Somayeh Arabzadeh
NANiusha Ameli
Niusha Ameli
AZAtefeh Zeinoddini
Atefeh Zeinoddini
FRFarzin Rezaei
Farzin Rezaei
MFMehdi Farokhnia
Mehdi Farokhnia
SAShahin Akhondzadeh
Shahin Akhondzadeh

4 October 2016 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
AGA. Ghajar
A. Ghajar
SNS. M. Neishabouri
S. M. Neishabouri
NVN. Velayati
N. Velayati
LJL. Jahangard
L. Jahangard
NMNasrin Matinnia
Nasrin Matinnia
SAS. Akhondzadeh
S. Akhondzadeh
Introduction: Saffron (Crocus sativus L.) has demonstrated antidepressant effects in clinical studies and extensive anxiolytic effects in experimental animal models. Methods: 66 patients with major depressive disorder accompanied by anxious distress were randomly assigned to receive either saffron (30 mg/day) or citalopram (40 mg/day) for 6 weeks. Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) were used to assess treatment effect during the trial. Results: 60 participants finished the study. Patients who received either saffron or citalopram showed significant improvement in scores of the Hamilton Rating Scale for Depression (P-value<0.001 in both groups) and Hamilton Rating Scale for Anxiety (P-value<0.001 in both groups). Comparison of score changes between the 2 trial arms showed no significant difference (P-value=0.984). Frequency of side effects was not significantly different between the 2 groups. Discussion: The present study indicates saffron as a potential efficacious and tolerable treatment for major depressive disorder with anxious distress. * The first three authors contributed equally in this study.